BioCentury This Week to Celebrate Its 100th Show This Sunday

<p> Milestone Episode Features an In-Depth Discussion of the Collaborative Triangle of Drug Development </p>

REDWOOD CITY, CA and WASHINGTON, DC--(Marketwire -08/16/12)- BioCentury This Week TV, the first biotechnology public affairs program to be broadcast on a major U.S. television station -- and webcast around the world -- will air its 100th show this Sunday, August 19th. The program is a partnership between BioCentury Publications, Inc. and the Gannett-owned CBS affiliate WUSA9 in Washington, D.C.

This milestone broadcast will feature an in-depth discussion of the "collaborative triangle" -- how university researchers, patient groups, and biopharma companies are working together to advance drug development.

Special guests Dr. William Nelson, Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Dr. Ellen Sigal, Chair and Founder of Friends of Cancer Research, and Dr. N. Anthony Coles, President and CEO of Onyx Pharmaceuticals Inc., will join BioCentury This Week Host and Washington Senior Editor Steve Usdin for this special episode.

"BioCentury This Week was created to provide a platform for the life science community -- scientists, researchers, regulators, executives, investors, politicians, patient groups, and public policy makers -- to discuss and debate the issues vital to the advancement of public health," said David Flores, President & CEO of BioCentury. "The topic for the 100th show, The Collaborative Triangle, epitomizes this vision."

"This milestone proves that creating compelling, relevant and world-class content for life science stakeholders 52 weeks a year is a sustainable and thriving broadcast model," said Allan Horlick, Executive Producer of the Power Block public affairs programs on WUSA. "WUSA has been delighted to partner with BioCentury on these first 100 shows, and we greatly appreciate the continued leadership provided by our Charter Sponsors, Biogen Idec and the Biotechnology Industry Organization (BIO)."

BioCentury This Week has provided an independent venue for more than 200 leaders from more than 160 organizations, including members of Congress, regulators, patient and advocacy organizations, medical societies, think tanks, research organizations and universities, biotech and pharma companies, and members of the Wall Street and venture capital communities.

The first 100 shows of BioCentury This Week have included a two-part debate on scientific risk and regulatory risk featuring Dr. Janet Woodcock of FDA and Wall Street's Jonathan Leff of Warburg Pincus; a discussion on the future of translational science in the laboratory of NIH Director Dr. Francis Collins; and new thinking being brought to Rockefeller University and the University of California by former Genentech executives Dr. Marc Tessier-Lavigne and Dr. Susan Desmond-Hellmann.

Other thought leaders on BioCentury This Week have included FDA Commissioner Dr. Margaret Hamburg; NICE Chairman Sir Michael Rawlins; Europe's IMI Executive Director Dr. Michel Goldman; FasterCures Chairman Michael Milken; former Senator Birch Bayh; Johnson & Johnson Worldwide Chairman of Pharmaceuticals Dr. Paul Stoffels; Genzyme CEO Dr. David Meeker; Astellas Venture Management President & CEO Sakae Asanuma; Google Venture's Dr. Krishna Yeshwant; U.S. Representative Michael Burgess of Texas; Institute of Medicine President Dr. Harvey Fineberg; and Nobel Prize winner Dr. Barry Marshall.

The complete showcase of programs can be seen in the Show Guide at www.biocenturytv.com.

BioCentury This Week is the only weekly, independent public affairs program covering the biopharma industry. It is broadcast on WUSA Channel 9 in Washington on Sundays at 8:30 a.m., EDT as part of the WUSA Sunday Power Block lineup, which includes CBS Sunday Morning; Face the Nation; This Week in Defense News; Platts Energy Week; and The McLaughlin Group.

The show can also be seen in an expanding number of markets in the PBS network including Anchorage, Alaska; Columbus, Ohio; Houston, Texas; Juneau, Alaska; Raleigh / Durham, N.C.; Sacramento, Calif.; San Francisco, Calif.; Topeka, Kans.; and Wheeling, W.Va. It is continuously available online at www.biocenturytv.com.

For sponsorship opportunities, contact Tom Carey, Vice President of Commercial Operations at tcarey@biocentury.com.

About BioCentury

Now in its 20th year, BioCentury Publications, Inc. provides essential biopharma industry intelligence to a global audience of biotech and pharmaceutical executives, investors, public policy specialists and the scientific community. This audience has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications and data products.

BioCentury's titles include the flagship BioCentury®, the Bernstein Report on BioBusiness; its SciBX: Science-Business eXchange™ translational science partnership with Nature Publishing Group; and its BioCentury Extra™ online daily newspaper. These timely journals are backed by BCIQ: BioCentury Online Intelligence™, an online business intelligence resource. BioCentury also produces its BioCentury This Week biotech public affairs television program in partnership with the Gannett-owned WUSA9 CBS affiliate in Washington, D.C. The program is aired in Washington each Sunday as part of the WUSA9 Sunday Morning Power Block, and distributed globally online at www.biocenturytv.com.

BioCentury also organizes life science investment conferences on Wall Street and in Europe.

For more information, visit www.biocentury.com and www.biocenturytv.com.